Chris has over 15 years of senior management experience as President, CBO and CFO of various private and public life sciences, medical technology, and technology companies.  Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees. 

During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies.   From 2007 – 2013 he served as the Chief financial Officer at  Anthera Pharmaceuticals, a pharmaceutical development company, and from 2010 – 2013 also served as Chief Business Officer at Anthera Pharmaceuticals.  Most recently beginning in 2014, Chris was interim CEO and subsequently CFO for Hansen Medical (HNSN) until the sale of the company to Auris Robotics in July 2016.  Chris has also served as a partner in FLG Partners since January 2014.

Chris earned his B.S. from California Polytechnic State University – San Luis Obispo, and a MBA from St Mary’s University.  Chris currently sits on the Board of Directors of Epibiome.

Dr. Ronald L. Shazer, M.D., M.B.A. joined Inspyr Therapeutics in August 2016 as Senior Vice President and Chief Medical Officer. Previously Dr. Shazer served as TRACON Pharmaceuticals Inc., Chief Medical Officer since October 2015. Dr. Shazer served as Senior Director, Clinical Lead Oncology at Pfizer where he led the clinical development of multiple oncology compounds including antibody drug conjugates, dual targeting T-cell engaging antibodies, and immuno-oncology small molecules. Prior to Pfizer, he served as a Director, Global Clinical Research Oncology at Bristol-Myers Squibb from 2011 to 2013 and served as the study lead on the registrational study for elotuzumab (Empliciti™), that subsequently received FDA approval. Prior to Bristol-Myers Squibb, he served as the Head of Clinical Development at Arena Pharmaceuticals during the filing of the NDA for lorcaserin (Belviq®). Dr. Shazer held academic positions in the Department of Medicine at the University of California, San Diego, University of California, Los Angeles School of Medicine, and Cedars-Sinai Medical Center. He completed his residency in internal medicine at Cedars-Sinai Medical Center in 2004. Dr. Shazer earned his B.A. in Economics from the University of California, San Diego, M.D. from the New York Medical College and M.B.A from the Anderson School of Management, University of California, Los Angeles.

Russell B. Richerson, PhD, joined Inspyr in September 2009. He has over 25 years of experience in the Biotechnology/Diagnostics industry, including 11 years at Abbott Laboratories in numerous management roles. He also has extensive experience in senior research and development positions at companies such as Boehringer Mannheim, Du Pont, Prometheus Laboratories, Ventana Medical Systems, and the Molecular Profiling Institute. Dr. Richerson recently served on the board of the International Genomics Consortium (IGC), a non-profit medical research organization located in Phoenix, Arizona. Dr. Richerson received his PhD from the University of Texas at Austin in 1983

Peter E. Grebow, PhD, joined the board in May 2012. He currently is President and founder of P.E. Grebow Consulting, Inc., which he formed in 2011. He has also served as Executive Vice President of Research and Development at Eagle Pharmaceuticals, Inc. since October 2013. Before becoming a director at Inspyr, Dr. Grebow held several key positions with Cephalon, Inc., including Executive Vice President of Cephalon Ventures, Executive Vice President of Technical Operations, Senior Vice President of Worldwide Business Development and Senior Vice President of Drug Development. Prior to joining Cephalon, Dr. Grebow served as Vice President Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc., and as director of Optimer Pharmaceuticals (NASDAQ: OPTR) . Since 2011, he has held directorships at Q Holdings, Inc., and Complexa, Inc. Dr. Grebow received his PhD in physical biochemistry from the University of California, Santa Barbara, in 1973.

Dr. Bo Jesper Hansen, MD, PhD Founded Scandinavian Medical Research, during which company Dr. Hansen served as Medical Advisor for Synthélabo, Pfizer, Inc., Pharmacia Corporation and Yamanouchi Pharmaceutical Co. Ltd.

He served as Chief Executive Officer and President of Swedish Orphan International AB (SOI AB) from 1998 to 2010 and also served as a Director of the Board of Swedish Orphan International AB during the same period, until the merger with Biovitrum AB in January 2010, forming Swedish Orphan Biovitrum (SOBI; NASDAQ:OMX). Dr. Hansen has been with Swedish Orphan International AB since 1993, where he grew it from a small Nordic-focused niche specialty-/Orphan drug pharma to an international organization, with over 60 products across Europe.

Prior to joining Swedish Orphan International AB, Dr. Hansen also co-founded the Shared Clinic “The Prostate Clinic” in Denmark.

Dr. Hansen's experience includes orphan drug research and development, international marketing and contract negotiations with extensive knowledge within regulatory, pharmacovigilance, medical marketing and business development, and he has close collaborations in the Orphan Drug area at executive level.

Currently, Dr. Hansen was Executive Chairman of Swedish Orphan Biovitrum AB (SOBI AB) from the merger in Jan 2010 until May 2016, Executive Chairman of TopoTarget A/S (TOPO; NASDAQ:OMX) since August, 2012 and has served as its Chairman from April, 2010, untill the merger with BioAlliance SAS in August 2014, forming Onxeo SA/Onxeo A/S; and since October 1, 2013 Chairman of Karolinska Development AB (KDEV; NASDAQ:OMX). He served as a non-executive Director of Gambro AB from august 2010-Dec 2012, when Gambro AB was acquired by Baxter; and as a non-executive Director in Zymenex A/S from 2008 until August 2013, when Zymenex was acquired by Chiesi Pharmaceutici. Furthermore, Dr. Hansen serves as a non-executive Director of Orphazyme ApS, Newron Pharmaceuticals SpA (NWRN; SIX), ABLYNX NV (NYSE Euronext Brussels), CMC AB, and Genspera, Inc. (GNSZ; NASDAQ) since August 2010. Dr. Hansen has been a Member of the Supervisory Board at Novagali Pharma S.A. since June 22, 2010 until Dec 2011 when Novagali Pharma S.A. was acquired by Santen. Dr. Hansen was also a non-executive Director of Hyperion Therapeutics (HPTX; NASDAQ), Inc. since April 2011 until the March 2015, when Hyperion Therapeutics was acquired by HORIZON. Dr. Hansen, is Senior Business Advisor for the venture funds, Aescap 2.0, and HBM Ventures, and Venture Partner at Wellington Partners. Dr. Hansen also serves as an Expert Evaluator of Calls to the European Commission’s 7th Framework Programme for Research (FP7-HEALTH-2012 and FP7-HEALTH-2013).

He is the author of more than 40 publications in international peer-review scientific journals and is an experienced presenter at international scientific congresses. Dr. Hansen is a Doctor of Medicine and holds an MD and a PhD from the University of Copenhagen.

Scott V. Ogilvie, has served as a director on our board since February 2008. Mr. Ogilvie is currently the President of AFIN International, Inc., an international private equity and strategic advisory firm, which he founded in 2006. Prior to December 31, 2009, he was CEO of Gulf Enterprises International, Ltd, an investment and strategic advisory company with primary activities in the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group, Inc., an investment manager, a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill, Farrer & Burrill, and has extensive public and private corporate management and board experience in finance, real estate, and life science and technology companies. During the past 5 years, Mr. Ogilvie has served on the board of directors of Innovative Card Technologies, Inc. (OTCBB:INVC), Preferred Voice, Inc., (OTCBD:PRFV), Inspyr Therapeutics, Inc. (OTCBB: GNSZ) and Research Solutions, Inc. (OTCBB:RSSS).